Search Results - "Heitmüller, Christina"

Preclinical study of CD19 detection methods post tafasitamab treatment by Ilieva, Kristina, Eberl, Markus, Jaehrling, Jan, Blair, Derek, Patra-Kneuer, Maria, Boxhammer, Rainer, Alvarez Arias, Diana, Heitmüller, Christina

“…Introduction Several CD19 targeted antibody-based therapeutics are currently available for patients with diffuse large B-cell lymphoma (DLBCL), including the…”
Get full text

Activity of tafasitamab in combination with rituximab in subtypes of aggressive lymphoma by Patra-Kneuer, Maria, Chang, Gaomei, Xu, Wendan, Augsberger, Christian, Grau, Michael, Zapukhlyak, Myroslav, Ilieva, Kristina, Landgraf, Karin, Mangelberger-Eberl, Doris, Yousefi, Kasra, Berning, Philipp, Kurz, Katrin S., Ott, German, Klener, Pavel, Khandanpour, Cyrus, Horna, Pedro, Schanzer, Jürgen, Steidl, Stefan, Endell, Jan, Heitmüller, Christina, Lenz, Georg

“…Background Despite recent advances in the treatment of aggressive lymphomas, a significant fraction of patients still succumbs to their disease. Thus, novel…”
Get full text

Blockade of the CD47/SIRPα Checkpoint Potentiates the Anti-Tumor Efficacy of Tafasitamab by Mangelberger, Doris, Augsberger, Christian, Landgraf, Karin, Heitmüller, Christina, Steidl, Stefan

“…Introduction Tafasitamab (MOR208) is an Fc-enhanced, humanized, monoclonal antibody that targets CD19 and has shown promising clinical activity in patients…”
Get full text

Tafasitamab in Combination with a CD20xCD3 Bispecific T-Cell Engager Significantly Prolongs Survival in Preclinical Lymphoma Models by Schaadt, Eveline, Heitmüller, Christina, Peters, Solveig, Ilieva, Kristina, Blair, Derek, Huth, Christiane, Bartel, Dominik, Zapf, Sandra, Eberl, Markus, Mangelberger-Eberl, Doris, Giles, Frank, Corvey, Carsten

“…R-CHOP remains the standard of care for newly diagnosed DLBCL patients. However, 30-40% of patients are refractory or relapse after initial response to the…”
Get full text

The Sumoylation Inhibitor TAK-981 in Combination with the CD19-Targeting Antibody Tafasitamab Shows Enhanced Anti-Tumor Activity in Preclinical B-Cell Lymphoma Models by Patra-Kneuer, Maria, Nakamura, Akito, Song, Keli, Grossman, Stephen, Polzer, Andrea, Ginzel, Carmen, Steidl, Stefan, Berger, Allison J, Proscurshim, Igor, Heitmüller, Christina

“…Introduction TAK-981 is a first-in-class small molecule inhibitor of the SUMO activating enzyme currently in Phase I/II clinical trials. TAK-981 has been shown…”
Get full text

Uncovering the Enemy: Single-Cell Transcriptional Profiling of Measurable Residual Disease (MRD) Cells by Kazerani, Maryam, Wange, Lucas, Tast, Benjamin, Solovey, Maria, Nixdorf, Daniel, Rohrbacher, Lisa, Heitmüller, Christina, Koehnke, Thomas, Schnorfeil, Frauke, Grunwald, Victoria V, Spiekermann, Karsten, Metzeler, Klaus H., Hopfner, Karl-Peter, Enard, Wolfgang, Buecklein, Veit L, Subklewe, Marion

Get full text

The Combination of Tafasitamab and Rituximab Increases Cytotoxicity Against Lymphoma Cells I n Vitro by Patra, Maria, Augsberger, Christian, Ginzel, Carmen, Polzer, Andrea, Landgraf, Karin, Bartel, Dominik, Ness, Daniel, Steidl, Stefan, Heitmüller, Christina, Schanzer, Juergen, Endell, Jan

“…Introduction Tafasitamab (MOR208) is a CD19-targeting, Fc effector function-enhanced antibody that has shown promising clinical activity in patients with…”
Get full text

The Combination of Tafasitamab and Rituximab Increases Cytotoxicity Against Lymphoma Cells In Vitro by Patra, Maria, Augsberger, Christian, Ginzel, Carmen, Polzer, Andrea, Landgraf, Karin, Bartel, Dominik, Ness, Daniel, Steidl, Stefan, Heitmüller, Christina, Schanzer, Juergen, Endell, Jan

“…Introduction Tafasitamab (MOR208) is a CD19-targeting, Fc effector function-enhanced antibody that has shown promising clinical activity in patients with…”
Get full text

Affinity of Anti-CD19 Antibodies Determines Subsequent CART19 Activation, Apoptosis and CRS in Preclinical Models by Sakemura, R. Leo, Manriquez Roman, Claudia, Mai, Long K., Kimball, Brooke L., Huynh, Truc, Feigin, Jennifer M., Girsch, James H., Sirpilla, Olivia L., Yun, Kun, Stewart, Carli M., Gutierrez Ruiz, Omar, Can, Ismail, Ogbodo, Ekene, Kankeu Fonkoua, Lionel Aurelien, Hefazi, Mehrdad, Ruff, Michael W., Jaehrling, Jan, Ilieva, Kristina, Patra-Kneuer, Maria, Heitmüller, Christina, Steidl, Stefan, Siegler, Elizabeth L., Kenderian, Saad S.

“…Our group has reported that transient CD19 antigen masking of leukemic cells with the CD19 monoclonal antibody (mAb), tafasitamab, resulted in reduction of…”
Get full text

Blocking the CD47-Sirpa Axis Enhances Tafasitamab-Mediated Phagocytosis by Biedermann, Alexander, Mangelberger-Eberl, Doris, Mougiakakos, Dimitrios, Büttner-Herold, Maike, Flamann, Cindy, Kellner, Christian, Altmeyer, Sarah, Bittenbring, Jörg, Augsberger, Christian, Patra-Kneuer, Maria, Landgraf, Karin, Ilieva-Babinsky, Kristina, Haskamp, Stefan, Beier, Fabian, Voelkl, Simon, Pallasch, Christian, Jacobs, Benedikt, Steidl, Stefan, Heitmüller, Christina, Mackensen, Andreas, Bruns, Heiko

Get full text

CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS by Sakemura, R Leo, Manriquez Roman, Claudia, Horvei, Paulina, Siegler, Elizabeth L, Girsch, James H, Sirpilla, Olivia L, Stewart, Carli M, Yun, Kun, Can, Ismail, Ogbodo, Ekene J, Adada, Mohamad M, Bezerra, Evandro D, Kankeu Fonkoua, Lionel Aurelien, Hefazi, Mehrdad, Ruff, Michael W, Kimball, Brooke L, Mai, Long K, Huynh, Truc N, Nevala, Wendy K, Ilieva, Kristina, Augsberger, Christian, Patra-Kneuer, Maria, Schanzer, Jürgen, Endell, Jan, Heitmüller, Christina, Steidl, Stefan, Parikh, Sameer A, Ding, Wei, Kay, Neil E, Nowakowski, Grzegorz S, Kenderian, Saad S

“…In the development of various strategies of anti-CD19 immunotherapy for the treatment of B-cell malignancies, it remains unclear whether CD19 monoclonal…”
Get full text

CD19 Antigen Occupancy on Cancer Cells with the CD19 Monoclonal Antibody Tafasitamab Improves the Activation, Antitumor Efficacy, and Safety Profile of CART19 Cell Therapy by Sakemura, Reona Leo, Manriquez-Roman, Claudia, Horvei, Paulina, Cox, Michelle J., Huynh, Truc, Girsch, James H., Sirpilla, Olivia, Yun, Kun, Stewart, Carli M., Can, Ismail, Ogbodo, Ekene J., Adada, Mohamad M., Kankeu Fonkoua, Lionel A., Hefazi, Mehrdad, Ruff, Michael W., Ilieva-Babinsky, Kristina, Augsberger, Christian, Patra-Kneuer, Maria, Heitmüller, Christina, Steidl, Stefan, Parikh, Sameer A., Ding, Wei, Kay, Neil E., Nowakowski, Grzegorz S., Siegler, Elizabeth L., Kenderian, Saad S.

Get full text

The Impact of Prior Treatment with a CD19 Targeting Monoclonal Antibody on Subsequent Treatment with CD19 Targeting CART Cell Therapy in Preclinical Models by Sakemura, Reona, Horvei, Paulina, Manriquez-Roman, Claudia, Ogbodo, Ekene J., Tapper, Erin E., Siegler, Elizabeth L., Stewart, Carli M., Schick, Kendall J., Can, Ismail, Adada, Mohamad M., Bezerra, Evandro D., Kankeu Fonkoua, Lionel A., Hefazi, Mehrdad, Ruff, Michael W., Augsberger, Christian, Schanzer, Juergen, Patra-Kneuer, Maria, Heitmüller, Christina, Steidl, Stefan, Endell, Jan, Ding, Wei, Parikh, Sameer A., Slager, Susan L., Kay, Neil E., Nowakowski, Grzegorz S., Cox, Michelle J., Kenderian, Saad S.

“…With the development of various strategies of anti-CD19 immunotherapy for treatment of B cell malignancies, it remains to be elucidated whether CD19 targeting…”
Get full text

Targeting Intracellular WT1 in AML Utilizing a T Cell Bispecific Antibody Construct: Augmenting Efficacy through Combination with Lenalidomide by Klein, Christian, Augsberger, Christian, Xu, Wei, Heitmüller, Christina, Hanisch, Lydia, Sam, Johannes, Pulko, Vesna, Schönle, Anne, Challier, John, Carpy, Alejandro, Konstandin, Nikola, Rothe, Maurine, Hänel, Gerulf, Bücklein, Veit, Lichtenegger, Felix S., Tunger, Antje, Schmitz, Marc, von Bergwelt, Michael, Spiekermann, Karsten, Umana, Pablo, Subklewe, Marion

“…Antibody-based immunotherapy represents a promising strategy to target chemo-resistant leukemic cells. However, current antibody-based approaches are…”
Get full text

Abstract 6329: Preclinical study of CD19 detection methods using monoclonal antibodies post tafasitamab treatment by Ilieva, Kristina M., Eberl, Markus, Jaehrling, Jan, Ginzel, Carmen, Voland, Britta, Zankl, Michaela, Polzer, Andrea, Blair, Derek, Boxhammer, Rainer, Wang, Liang-Chuan, Arias, Diana Alvarez, Heitmüller, Christina

“…Abstract Introduction Tafasitamab (TAFA), an Fc-enhanced antibody immunotherapy against CD19 received accelerated/conditional approval in relapsed or…”
Get full text

13 - Transient CD19 Occupancy with Tafasitamab at the Time of Anti-CD19 Chimeric Antigen Receptor T (CART19) Cell Infusion Diminishes Severity and Incidence of CRS and Improves the Therapeutic Index of CART19 Cell Therapy in Preclinical Models by Sakemura, R. Leo, Roman, Claudia Manriquez, Horvei, Paulina, Huynh, Truc N, Girsch, James H., Sirpilla, Olivia, Yun, Kun, Stewart, Carli M., Can, Ismail, Ogbodo, Ekene J., Adada, Mohamad M., Kankeu Fonkoua, Lionel Aurelien, Hefazi, Mehrdad, Ruff, Michael W., Ilieva-Babinsky, Kristina, Augsberger, Christian, Patra-Kneuer, Maria, Heitmüller, Christina, Steidl, Stefan, Parikh, Sameer A., Ding, Wei, Kay, Neil E., Nowakowski, Grzegorz S, Siegler, Elizabeth L., Kenderian, Saad S.

Get full text

Transient CD19 Occupancy with Tafasitamab at the Time of Anti-CD19 Chimeric Antigen Receptor T (CART19) Cell Infusion Diminishes Severity and Incidence of CRS and Improves the Therapeutic Index of CART19 Cell Therapy in Preclinical Models by Sakemura, R. Leo, Roman, Claudia Manriquez, Horvei, Paulina, Huynh, Truc N, Girsch, James H., Sirpilla, Olivia, Yun, Kun, Stewart, Carli M., Can, Ismail, Ogbodo, Ekene J., Adada, Mohamad M., Kankeu Fonkoua, Lionel Aurelien, Hefazi, Mehrdad, Ruff, Michael W., Ilieva-Babinsky, Kristina, Augsberger, Christian, Patra-Kneuer, Maria, Heitmüller, Christina, Steidl, Stefan, Parikh, Sameer A., Ding, Wei, Kay, Neil E., Nowakowski, Grzegorz S, Siegler, Elizabeth L., Kenderian, Saad S.

Get full text

200 - The Impact of Prior Treatment with a CD19 Targeting Monoclonal Antibody on Subsequent Treatment with CD19 Targeting CART Cell Therapy in Preclinical Models by Sakemura, Reona, Horvei, Paulina, Roman, Claudia Manriquez, Ogbodo, Ekene J., Tapper, Erin E., Siegler, Elizabeth L., Cox, Michelle J., Stewart, Carli M., Schick, Kendall J., Can, Ismail, Adada, Mohamad M., Bezerra, Evandro D., Kankeu Fonkoua, Lionel Aurelien, Hefazi, Mehrdad, Ruff, Michael W., Augsberger, Christian, Schanzer, Jürgen, Patra-Kneuer, Maria, Heitmüller, Christina, Steidl, Stefan, Endell, Jan, Ding, Wei, Parikh, Sameer A., Slager, Susan L., Kay, Neil E., Nowakowski, Grzegorz S, Kenderian, Saad S.

Get full text

The Impact of Prior Treatment with a CD19 Targeting Monoclonal Antibody on Subsequent Treatment with CD19 Targeting CART Cell Therapy in Preclinical Models by Sakemura, Reona, Horvei, Paulina, Roman, Claudia Manriquez, Ogbodo, Ekene J., Tapper, Erin E., Siegler, Elizabeth L., Cox, Michelle J., Stewart, Carli M., Schick, Kendall J., Can, Ismail, Adada, Mohamad M., Bezerra, Evandro D., Kankeu Fonkoua, Lionel Aurelien, Hefazi, Mehrdad, Ruff, Michael W., Augsberger, Christian, Schanzer, Jürgen, Patra-Kneuer, Maria, Heitmüller, Christina, Steidl, Stefan, Endell, Jan, Ding, Wei, Parikh, Sameer A., Slager, Susan L., Kay, Neil E., Nowakowski, Grzegorz S, Kenderian, Saad S.

Get full text